Thrombosis and hormone replacement therapy in the menopausal

Hormonal replacement therapy (HRT) for treatment of menopausal and climacterically complaints is associated with a three- to four -fold increase in the risk of thrombosis. The actual risk of thrombosis depends on the type and the hormone content of the preparation in use but also on the individual risk factors of the patient.

This means that prior to the commencement of HRT a careful evaluation of the individual’s thrombotic risk should be performed in every woman in order to choose the most effective, thrombosis risk adapted hormone combination and method of application accordingly. On the other hand, a history of thrombosis does not necessarily contraindicate the use of hormonal replacement therapy.

Copyright © 2024 - KIWU - von Tempelhoff

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.